| Literature DB >> 31099302 |
Martin Koestenberger1,2, Hannes Sallmon2,3, Alexander Avian4, Massimiliano Cantinotti5, Andreas Gamillscheg1,2, Stefan Kurath-Koller1,2, Sabrina Schweintzger1, Georg Hansmann2,6.
Abstract
Determination of biventricular dimensions, function, and ventricular-ventricular interactions (VVI) is an essential part of the echocardiographic examination in adults with pulmonary hypertension (PH); however, data from according pediatric studies are sparse. We hypothesized that left and right heart dimensions/function and VVI variables indicate disease severity and progression in children with PH. Left heart, right heart, and VVI variables (e.g. end-systolic LV eccentricity index [LVEI], right ventricular [RV]/left ventricular [LV] dimension ratio) were echocardiographically determined in 57 children with PH, and correlated with New York Heart Association (NYHA) functional class (FC), N-terminal-pro brain natriuretic peptide (NT-proBNP), and invasive hemodynamic variables (e.g. pulmonary vascular resistance index [PVRi]). Clinically sicker patients (higher NYHA FC) had lower LV ejection fraction (LVEF) and higher LVEI - a surrogate of LV compression. In PH children, the ratio of systolic pulmonary arterial pressure divided by systolic systemic arterial pressure (sPAP/sSAP) and the PVRi correlated well with the LVEI ( P < 0.001). Patients with more severe PH (sPAP/sSAP ratio, PVRi) had increased RV/LV and right-to-left atrial dimension ratios ( P < 0.01). When stratified using NYHA-FC, sicker PH children had greater RV and right atrial dimensions with lower exercise capacity, while the tricuspid annular plane systolic excursion as surrogate for longitudinal systolic RV function decreased. Consistent with previous studies, serum NT-proBNP correlated with both, sPAP/sSAP ratio ( P < 0.001) and NYHA FC ( P < 0.01). Taken together, the VVI variables LVEI and RV/LV dimension ratio are associated with lower FC, worse hemodynamics, and higher NT-proBNP levels, thus highlighting the importance of ventricular interdependence in pediatric PH.Entities:
Keywords: New York Health Association functional class; left ventricular eccentricity index; pediatric pulmonary hypertension; ventricular–ventricular interactions
Year: 2019 PMID: 31099302 PMCID: PMC6542130 DOI: 10.1177/2045894019854074
Source DB: PubMed Journal: Pulm Circ ISSN: 2045-8932 Impact factor: 3.017
Demographic data of our 57 patients with PH.
| All PH patients | |
| Fulfilled inclusion criteria (n) | 57 |
| Female (n (%)) | 24 (42) |
| Age at baseline (years) (range) | 5.7 (0.6–18.2) |
| Body weight (kg) (range) | 20.8 (4.9–86.5) |
| Body length (cm) (range) | 127 (50–187) |
| BSA range (m2) | 0.2–1.92 |
| NYHA-FC/ROSS score | |
| I (n) | 18 |
| II (n) | 27 |
| III (n) | 12 |
| PH medication (n) | |
| Sildenafil (single) | 13 |
| Bosentan | 4 |
| Macitentan | 8 |
| Bosentan, sildenafil (comb) | 10 |
| Macitentan, sildenafil | 18 |
| Selexipag (triple comb) | 4 |
| Calcium antagonists | 3 |
| PAH-CHD (n = 26) | |
| TRV (m/s) | 3.9 (3.0–4.9) |
| sPAP/sSAP (%) | 71 (39–102) |
| mPAP (mmHg) (mean ± range) | 37 (27–55) |
| PVRi (WU) (mean ± range) | 3.9 (2.2–15.3) |
| TAPSE (mm) | 1.54 (1.21–1.74) |
| PAAT (ms) | 75 ± 19 |
| Diagnosis (n) | |
| AVSD | 12 |
| VSD | 10 |
| PA with VSD | 4 |
| IPAH (n = 12) | |
| TRV (m/s) | 4.4 (3.3–5.6) |
| sPAP/sSAP (%) | 88 (44–118) |
| mPAP (mmHg) (mean ± range) | 47 (32–91) |
| PVRi (WU) (mean ± range) | 8.9 (3.1–20.4) |
| TAPSE (mm) | 1.32 (1.24–1.66) |
| PAAT (ms) | 70 ± 16 |
| PH-BPD (n = 19) | |
| TRV (m/s) | 3.4 (2.9–4.3) |
| sPAP/sSAP (%) | 62 (38–85) |
| mPAP (mmHg) (mean ± range) | 35 (27–54) |
| PVRi (WU) (mean ± range) | 5.6 (3.0–15.8) |
| TAPSE (mm) | 1.12 (0.85–1.55) |
| PAAT (ms) | 65 ± 16 |
Values are presented as n or median (range) unless otherwise specified.
AVSD, atrioventricular septal defect; BSA, body surface area; BPD, bronchopulmonary dysplasia; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean pulmonary arterial pressure; NYHA, New York Heart Association; PA, pulmonary atresia; PAAT, pulmonary artery acceleration time; PH-CHD, pulmonary hypertension secondary to congenital heart disease; PVRi, pulmonary vascular resistance indexed; RV, right ventricle; sPAP/sSAP, systolic pulmonary arterial pressure/systolic systemic arterial pressure; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion; TRV, tricuspid regurgitation velocity; VSD, ventricular septal defect; WU, Wood Units.
Fig. 3.(a) Differences in RA/LA area ratio according to NYHA FC/Ross Score and (b) Differences in RV/LV dimension ratio according to NYHA FC/Ross Score. FC, functional class; LA, left atrium; RA, right atrium; LV, left ventricle; RV, right ventricle.
Fig. 4.(a) Differences according to NYHA FC/Ross Score and the LVEF and (b) Differences according to NYHA FC/Ross Score and the LVEI. FC, functional class; LVEF, left ventricular ejection fraction; LVEI, left ventricular eccentricity index.
Fig. 1.(a) Association of the LVEF with the sPAP/sSAP ratio (r = −0.810, P < 0.001) and (b) Association of the LVEF with the PVRi (ρ = −0.479, P = 0.001). LVEF, left ventricular ejection fraction; PVRi, indexed pulmonary vascular resistance; sPAP, systolic pulmonary arterial pressure, sSAP, systolic systemic arterial pressure.
Fig. 2.(a) Association of the TAPSE with the sPAP/sSAP ratio and (b) Differences in TAPSE according to the NYHA FC/Ross Score. FC, functional class; sPAP, systolic pulmonary arterial pressure, sSAP, systolic systemic arterial pressure; TAPSE, tricuspid annular plane systolic excursion.